Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 20, 2017

Primary Completion Date

August 20, 2021

Study Completion Date

December 30, 2022

Conditions
Hiv
Interventions
DRUG

Romidepsin

5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART

DRUG

3BNC117

30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART

DRUG

Antiretrovirals

Combination antiretroviral therapy

Trial Locations (7)

8200

Dept. of Infectious Diseases, Aarhus University Hospital, Aarhus

Unknown

Department of Infectious Diseases, Aalborg

Department of Infectious Diseases, Copenhagen

Department of Infectious Diseases, Hvidovre

Department of Infectious Diseases, Odense

Guy's and St Thomas', London

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Hvidovre University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

collaborator

Herning Hospital

OTHER

collaborator

Hammersmith Hospitals NHS Trust

OTHER

collaborator

St Mary's Hospital, London

OTHER

lead

Aarhus University Hospital

OTHER

NCT03041012 - Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART | Biotech Hunter | Biotech Hunter